Form 8-K
0001446159 False 0001446159 2021-08-11 2021-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, D.C. 20549





Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 11, 2021


Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)


(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

2915 Commers Drive, Suite 900

Eagan, Minnesota 55121

(Address of Principal Executive Offices) (Zip Code)

(651) 389-4800

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valuePOAINasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2021, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(a) Not applicable.

(b) Not applicable.

(c) Not applicable.

(d) Exhibits

99.1 Press Release dated August 11, 2021

104  Cover Page Interactive Data File (embedded within the Inline XBRL document)



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Predictive Oncology Inc.
Date: August 11, 2021By: /s/ Bob Myers        
  Bob Myers
  Chief Financial Officer




Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update

MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021, and provided an update on business activities.

Q2 2021 Highlights:

“We are pleased with the progress our business segments are making as we conclude the first full year of operations for Soluble Biotech,” commented J. Melville Engle, Predictive Oncology Chief Executive Officer. “Soluble and TumorGenesis’ new GMP facilities are slated for completion by the end of 2021, which we expect will drive revenue growth opportunities as we meet the needs of researchers who are exploring ways to use the cancer cell’s own mechanisms to produce a target, expressed protein or biological target.”

“Predictive Oncology believes the results from this quarter show growth opportunities in our business segments, consistent with our goals and business objectives, and with even greater potential in the future. As we look towards the latter half of the year, we are confident that we will retain this trajectory as we invest in our people and our product offerings, supporting pharmaceutical companies to deliver more targeted approaches to therapy, increasing our footprint in this space and bringing value to our shareholders.”

Q2 2021 Financial results

The Company recorded revenue of $350,207 for the quarter, compared to $182,784 for the same quarter in 2020. G&A expenses decreased $1.13 million for the three months ended June 30, 2021 compared to 2020.

During the three months ended June 30, 2021, revenue increased to $350,207, an increase of approximately 92% from the previous year quarter. This included $34,910 from the Soluble reportable segment, the largest ever quarter in terms of revenue for that segment.

The gross profit margin was approximately 59% in the three ended June 30, 2021 compared to 53% in the prior year. Gross profit margins increased in the second quarter ofthe current year as costs were lower.

Operations expense increased by $46,680 to $567,796 in the three months ended June 30, 2021 compared to 2020, primarily due to higher costs related to staff and higher AI computing costs, partially offset by lower consulting expenses.

The Company’s sales and marketing expenses increased by $26,773 for the quarter to $159,788 compared to the same period in 2020, a direct result of commission expenditures in the Skyline Medical business, which itself saw an increase in revenue of $132,398 over the previous year quarter.

Net cash used in operating activities was $5,526,978 and $6,721,084 for the six months ended June 30, 2021 and June 30, 2020, respectively. Cash used in operating activities decreased in the 2021 period primarily because of the decrease in cash used for working capital and the lower operating costs related to the Helomics and Skyline business.

Net cash provided by financing activities was $50,363,456 and $9,874,355 for the six months ended June 30, 2021 and June 30, 2020, respectively. The cash provided in the six months ended June 30, 2021 was primarily due to proceeds from issuance of common stock and warrants in six financing transactions and the exercise of warrants by investors, in addition to proceeds from the issuance of common stock pursuant to the equity line agreement, offset by the repayment of outstanding debt, all of which are discussed in the Company’s 10-Q filing with the Securities and Exchange Commission.

About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.


  June 30,
 December 31,
  (unaudited) (audited)
Current Assets:        
Cash and cash equivalents $44,881,034   $ 678,332 
Accounts Receivable  196,520     256,878 
Inventories  317,826     289,535 
Prepaid Expense and Other Assets  241,799     289,490 
Total Current Assets  45,637,179     1,514,235 
Fixed Assets, net  3,950,613     3,822,700 
Intangibles, net  3,254,838     3,398,101 
Lease Right-of-Use Assets  1,131,795     1,395,351 
Other Long-Term Assets  124,096     116,257 
Goodwill  2,813,792     2,813,792 
Total Assets $56,912,313     13,060,436 
Current Liabilities:        
Accounts Payable $941,960   $ 1,372,070 
Notes Payable – Net of Discounts of $0 and $244,830  -     4,431,925 
Accrued Expenses and other liabilities  1,256,087     2,588,047 
Derivative Liability  229,620     294,382 
Deferred Revenue  154,345     53,028 
Lease Liability  640,353     597,469 
Total Current Liabilities  3,222,365     9,336,921 
Lease Liability – Net of current portion  554,716     845,129 
Other long-term liabilities  47,146     235,705 
Total Liabilities  3,824,227     10,417,755 
Stockholders’ Equity:        
Preferred Stock, 20,000,000 authorized inclusive of designated below        
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 and 79,246 shares outstanding  792     792 
Common Stock, $.01 par value, 100,000,000 shares authorized, 65,335,159 and 19,804,787 outstanding  653,352     198,048 
Additional paid-in capital  167,279,695     110,826,949 
Accumulated Deficit  (114,845,753)    (108,383,108)
Total Stockholders’ Equity  53,088,086     2,642,681 
Total Liabilities and Stockholders’ Equity $56,912,313    $13,060,436 


  2021   2020   2021   2020 
Revenue$350,207  $182,784  $630,524  $477,727 
Cost of goods sold 142,877   85,261   240,635   177,918 
Gross profit 207,330   97,523   389,889   299,809 
General and administrative expense 2,077,973   3,211,817   5,348,750   6,040,293 
Operations expense 567,796   521,116   1,142,608   1,069,869 
Sales and marketing expense 159,788   133,015   274,429   397,424 
Total operating loss (2,598,227)  (3,768,425)  (6,375,898)  (7,207,777)
Other income 57,033   52,965   85,292   52,968 
Other expense (1,829)  (729,837)  (236,801)  (1,846,912)
Gain (loss) on derivative instruments (30,909)  (422,081)  64,762   (394,974)
Gain on notes receivables associated with asset purchase -   1,290,000   -   1,290,000 
Net loss$(2,573,932) $(3,577,378) $(6,462,645) $(8,106,695)
Net loss attributable to common shareholders per common shares-basic and diluted$ (2,573,932) $ (3,577,378) $(6,462,645) $(8,106,695)
Loss per common share basic$(0.05) $(0.36) $(0.15) $(1.10)
Loss per common share diluted (0.05)  (0.36)  (0.15)  (1.10)
Weighted average shared used in computation - basic 51,581,762   9,838,152   44,089,157   7,362,240 
Weighted average shared used in computation - diluted 51,581,762   9,838,152   44,089,157   7,362,240 

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
[email protected]